Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Canagliflozin | Telmisartan | |
|---|---|---|
| Category | Pharmaceuticals | Pharmaceuticals |
| Standard Dose | — | — |
| Timing | — | — |
| Cycle Duration | — | — |
| Evidence Level | Moderate (longevity), Strong (cardiorenal) | Strong |
SGLT2 inhibitor originally developed for type 2 diabetes. Blocks glucose reabsorption in kidneys, creating a mild glucose deficit that activates AMPK and mimics caloric restriction. Extended lifespan in male mice in the ITP.
Angiotensin receptor blocker with partial PPAR-delta activity that supports blood-pressure control and metabolic resilience.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →